MedTrace Logo

Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia

NCT04509973 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2022-02-24

No results posted yet for this study

Summary

We aim to assess the benefits and harms of higher (12 mg) vs lower doses (6 mg) of dexamethasone on patient-centered outcomes in patients with COVID-19 and severe hypoxia.

Conditions

Interventions

DRUG

Dexamethasone

ATC code: H02AB02

Sponsors & Collaborators

  • Copenhagen Trial Unit, Center for Clinical Intervention Research

    collaborator OTHER

  • Centre for Research in Intensive Care (CRIC)

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Rigshospitalet, Denmark

    collaborator OTHER

  • The George Institute for Global Health, Australia

    collaborator OTHER

  • Scandinavian Critical Care Trials Group

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-27
Primary Completion
2021-06-17
Completion
2022-02-01

Countries

  • Denmark
  • India
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04509973 on ClinicalTrials.gov